8-KLeadership ChangesExhibits & Filings

Guardant Health, Inc. 8-K Report, Executive Changes (Sep 15, 2025)

Filed September 15, 2025For Securities:GH

Summary

Guardant Health, Inc. (GH) has announced a significant addition to its Board of Directors with the appointment of Alex M. Azar II, former U.S. Secretary of Health and Human Services. This move, effective September 12, 2025, increases the board size to 11 members and brings a wealth of experience in healthcare policy and leadership to the company. Mr. Azar's appointment is effective until the 2027 Annual Meeting of Stockholders and includes a role on the nominating and corporate governance committee. His compensation includes standard director awards of stock options and restricted stock units valued at $362,500, with a staggered vesting schedule over four years. This strategic appointment underscores Guardant Health's commitment to strengthening its governance and leveraging high-level expertise as it continues to advance its position in the liquid biopsy and precision oncology market.

Key Highlights

  • 1Alex M. Azar II, former U.S. Secretary of Health and Human Services, appointed to Guardant Health's Board of Directors.
  • 2Board size increased to 11 directors.
  • 3Mr. Azar's term as a Class III director will expire at the 2027 Annual Meeting of Stockholders.
  • 4Mr. Azar appointed to the nominating and corporate governance committee.
  • 5Standard director compensation package includes $362,500 in stock options and restricted stock units, vesting over four years.
  • 6No reportable transactions or arrangements with third parties related to Mr. Azar's appointment.

Frequently Asked Questions

The appointment of Alex M. Azar II, a former U.S. Secretary of Health and Human Services, is significant as it brings extensive experience in healthcare policy, regulation, and leadership to Guardant Health's Board. This expertise can be invaluable in navigating the complex healthcare landscape, informing strategic decisions, and enhancing the company's corporate governance.

Mr. Azar will receive the standard compensation for non-employee directors, which includes an initial award of stock options and restricted stock units, each valued at $362,500. These awards will vest over a four-year period, with a portion vesting one year after his appointment and the remainder vesting monthly over the subsequent three years, subject to continued service.

Mr. Azar has been appointed to the nominating and corporate governance committee of the Board. This role is crucial for overseeing board composition, director nominations, and corporate governance practices.

The filing states that there are no arrangements or understandings with any other person pursuant to which Mr. Azar was selected as a director, nor are there any reportable transactions in which he has an interest under Item 404(a) of Regulation S-K. He will also receive a standard indemnification agreement.